WhaleCreep

Propel Bio Management, LLC 13F holdings, Q3 2025

Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →

Propel Bio Management, LLC disclosed 16 US equity positions worth $99.9m in its Q3 2025 13F filing. The largest position was PAGPEUR at 23.2% of the reported book, followed by ACHV and AKERO THERAPEUTICS INC. Against the Q2 2025 filing, it opened 6 new positions, added to 2 and reduced 3 among the top 16 holdings.

← Q2 2025 · Q4 2025 →

What did Propel Bio Management, LLC own in Q3 2025? Top 16 positions

#StockSectorWeightValueSharesΔ sharesvs Q2 2025
1 PAGPEUR PLAINS GP HOLDINGS LP-CL 23.2%$23.2m1,272,360 0% held
2 ACHV ACHIEVE LIFE SCIENCES INC 11.9%$11.9m3,786,425 -38% reduced
3 AKERO THERAPEUTICS INC 10.9%$10.9m228,884 0% held
4 MIST MILESTONE PHARMACEUTICALS 10.3%$10.2m5,124,890 186% added
5 APLT APPLIED THERAPEUTICS INC 6.8%$6.8m11,285,420 0% held
6 PHAT PHATHOM PHARMACEUTICALS I 6.5%$6.5m552,927 -40% reduced
7 ABEO ABEONA THERAPEUTICS INC Healthcare 5.1%$5.1m974,022 0% held
8 DCTH DELCATH SYSTEMS INC 4.7%$4.7m438,509 94% added
9 CLDX CELLDEX THERAPEUTICS INC Healthcare 4.0%$4.0m155,000 – new
10 TCRX TSCAN THERAPEUTICS INC 3.5%$3.5m1,932,304 -7% reduced
11 CMPS COMPASS PATHWAYS PLC Healthcare 2.9%$2.9m510,000 – new
12 NKTR NEKTAR THERAPEUTICS Healthcare 2.8%$2.8m49,000 – new
13 JSPR JASPER THERAPEUTICS INC 2.5%$2.4m1,028,806 – new
14 ZVRA ZEVRA THERAPEUTICS INC 2.2%$2.2m231,874 0% held
15 VRDN VIRIDIAN THERAPEUTICS INC Healthcare 1.9%$1.9m90,000 – new
16 LONA ATHIRA PHARMA INC 0.6%$618.0k149,279 – new

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.